Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06940778 | LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS(BLENTI) | active not recruiting | — | 273 | Hospital do CoracaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 |
| clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06938906 | Multimodal Therapy Impact on Pancreatic Cancer Survival(MMTIPS) | active not recruiting | — | 405 | National Cheng Kung UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06938139 | Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy | active not recruiting | — | 90,000 | Fujian Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05128123 | Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF(SOCIAL-CHIEF) | active not recruiting | — | 1,600 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03428477 | EPA for Metastasis Trial 2(EMT2) | active not recruiting | Phase 3 | 418 | Mark A Hull, PhD FRCPOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06532331 | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 87 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06934070 | Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection | active not recruiting | — | 287 | Qiang XuOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04996095 | The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan | active not recruiting | — | 400 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03908788 | Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy(EmutRAS) | active not recruiting | N/A | 130 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04634058 | PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment | active not recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05083780 | Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer | active not recruiting | Phase 1 | 40 | Changhoon YooOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06920082 | Progressive Muscle Relaxation Exercises on Sleep, Fatigue and Pain in Pancreatic and Colon Cancer Patients | active not recruiting | N/A | 60 | Istanbul Sabahattin Zaim UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06056804 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | active not recruiting | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1) | active not recruiting | Phase 3 | 789 | Universitätsklinikum Hamburg-EppendorfOTHER | 8 | Mar 30, 2025 | clinicaltrials |
| NCT06443203 | Multimodal Prehabilitation in Colorectal Cancer Patients | active not recruiting | N/A | 112 | University Hospital of FerraraOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04749862 | Cancer Surveillance and Support(CANVAS) | active not recruiting | — | 565 | University of LeedsOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03200834 | Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON) | active not recruiting | N/A | 239 | G.V. Bondar Republican Cancer CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT01937780 | Anal Cancer Radiotherapy Study(ANCARAD) | active not recruiting | — | 75 | Oslo University HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma(BACAP) | active not recruiting | — | 1,700 | University Hospital, ToulouseOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05623787 | Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms(DWI-HighRisk) | active not recruiting | N/A | 30 | Laval UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06886022 | Diagnosis, Treatment, and Prevention of Colorectal Cancer Amid Abnormal Lipid Metabolism | active not recruiting | — | 1,000 | Tianjin Union Medical CenterOTHER | 0 | Mar 20, 2025 | clinicaltrials |
| NCT06886763 | HCC Innervation Assessment | active not recruiting | — | 300 | Hospices Civils de LyonOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05612477 | Blood Salvage in Orthotopic Liver Transplantation With HCC(SOLT) | active not recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06707025 | The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma(CD24CCA) | active not recruiting | — | 50 | Hadassah Medical OrganizationOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06877910 | Deciphering the Molecular Traits of Non-canonical Responders to Advance Personalized Therapy in Gastric Cancer | active not recruiting | — | 220 | Regina Elena Cancer InstituteOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04612309 | Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer(C-MSI) | active not recruiting | — | 100 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05765214 | Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes | active not recruiting | N/A | 120 | Charles Drew University of Medicine and ScienceOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04246203 | Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer(PROJECTION) | active not recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06867146 | MRD in PAAD Adjuvant Therapy | active not recruiting | N/A | 60 | Peking Union Medical College HospitalOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT06856382 | The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer | active not recruiting | — | 20 | Dong PengOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05165264 | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer(INGA) | active not recruiting | — | 600 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06853769 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer(LARC-nCR01) | active not recruiting | Early Phase 1 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06854146 | The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome | active not recruiting | — | 200 | Dong PengOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06852495 | the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes | active not recruiting | — | 200 | Dong PengOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04344158 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 3 | 648 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03795311 | Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)(FOLFIRINOX3) | active not recruiting | Phase 1 / Phase 2 | 32 | Centre Georges Francois LeclercOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06828718 | The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC)(NEO-EC) | active not recruiting | — | 1,000 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03255434 | LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy(LEANOX) | active not recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05491616 | Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study(SANO-3) | active not recruiting | Phase 2 | 77 | Erasmus Medical CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03899636 | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer(DIRECT) | active not recruiting | Phase 3 | 528 | Angiodynamics, Inc.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03899649 | A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer(DIRECT) | active not recruiting | — | 532 | Angiodynamics, Inc.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2025source: clinicaltrials